Dec. 6: Questions Toward a Cure
	What expectations do you have, and risks are you willing to take, when faced with the option of participating in clinical trials of therapies that might help develop a cure? These are essential questions community advocates are looking to answer as they begin working with researchers and regulatory agencies like the U.S. Food and Drug Administration (FDA) on the development of ethical human studies.

	Nov. 30: Getting to Zero: the Next Chapter of HIV
	The editor of BASELINE, a UK-based quarterly lifestyle magazine for people living with and affected by HIV and hepatitits, chimes in with an op-ed that discusses the evolution of HIV throughout the past 30 years and sheds light on major strides to date and the future.

	May. 25: What Would You Do to Cure HIV?
	Research geared toward curing HIV is experiencing a resurgence. With new enthusiasm and increased funding, researchers are beginning to plot new interventions to bombard the virus in unusual ways. The first round of studies is bound to carry serious health risks, however, and many will fail. The big unanswered questions are whether HIV-positive people will volunteer for these trials—and if so, whether the FDA and other regulators will let them.